Replies to post #323194 on Avid Bioservices Inc (CDMO)

[cjgaddy]

Thx much, North40k. Please do me a favor before I re-post the Attendee reports compilation with your latest one included…

For me, and others I’m sure, would you translate these abbreviations that you used (or give me hints so I can look them up and expand them for clarity)…
THANK YOU!

JHU = xxx

UPDATE – I think I’ve got these 3:
Dr. NK = xxx => I know now: PPHM’s Dr. Nikoletta Kallinteris
Dr. TK (s/b TG ?) = Tobias Guennel (Precision for Medicine)
PFM = Precision for Medicine, Frederick, MD

THIS SECTION:
N40K: “For now, I will not belabor my previous comments as to what Dr. Jedd Wolchok and other MSKCC personnel have told me in face-to-face conversations at SITC 2016, Wistar (Dec. 7, 2016), AACR 2017 or JHU in Baltimore(Dec. 7, 2017). Nor will I expand my comments re: conversations had with Dr NK(PPHM/CDMO) or Dr. TK(PFM) at SITC in Nov.2017. My remarks are already recorded here, and my comments last week to the CDMO BOD contain basically the same information, including the fact that PFM has acquired $200mm in additional funds and has >1000 employees world-wide.”
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137869635

[patientlywaiting]

"Frankly, those facts and remarks seemed to me to fall on deaf ears---the stolid, expressionless faces of BOD members while I spoke made me feel I was talking to an army or array of Chinese stone soldiers. I was pleased to see one BOD member take notes during my presentation(I hope it was not a grocery list for his wife when he returned home). It was like delivering remarks to a judicial bench of judges who were not sufficiently informed of the record[history] before them to know what questions to ask."

Thanks for the feedback. Seems to be the ongoing opinion.

[jq1234]

>> I began explaining that we had invested in past years some $550k in PPHM therapy technology, and once had ~ 500k shares of PPHM with a break-even point of $1.10/share. Now, with a reverse split behind us together with a change in focus and name of PPHM to CDMO, we hold ~73 shares CDMO with a break-even point of ~ $7.70/share.


Condolences to your over $280K loss on PPHM! Had you listened to Biotech Values board’s consensus for years that bavituximab had no clinical value based on its clinical data, your loss would have been more limited.

[geocappy1]

North

In my opinion there is an orchestrated proceed going on to lower the expectations of retails SHs. Mine is a gut feeling based on the responses of Lias. He is too quick to poo poo the IP in a public meeting. When you are trying to sell something you never never ever admit to a lack of interest unless of course you have an alternative agenda.